Alterations of Lymphoid Enhancer Factor-1 Isoform Expression in Solid Tumors and Acute Leukemias
Alterations of Lymphoid Enhancer Factor-1 Isoform Expression in Solid Tumors and Acute Leukemias作者机构:InstituteofLifeSciencesJiangsuUniversityZhenjiang212013China
出 版 物:《Acta Biochimica et Biophysica Sinica》 (生物化学与生物物理学报(英文版))
年 卷 期:2005年第37卷第3期
页 面:173-180页
核心收录:
学科分类:0710[理学-生物学] 0831[工学-生物医学工程(可授工学、理学、医学学位)] 1002[医学-临床医学] 0703[理学-化学] 100214[医学-肿瘤学] 10[医学]
基 金:This work is supported by grants from the José-Carreras Leukemia Foundation,the Deutsche Forschungsgemeinschaft(Mu 1328/2-3,Se 600/2-2,SFB293) the Deutsche Krebshilfe(10-1819-M2) the IZKF(Interdisziplinres Zentrum fr Klinische Forschung)at th
主 题:AML β-catenin isoform lymphoid enhancer factor(LEF-1) solid tumor
摘 要:Two major transcripts of lymphoid enhancer factor-1(LEF-1)have been *** longisoform with β-catenin binding domain functions as a transcriptional enhancer *** short isoformderives from an intronic promoter and exhibits dominant negative ***,alterations of LEF-1isoforms distribution have been described in colon *** the current study we employed a quantitativereal-time reverse transcription PCR method(TaqMan)to analyze expression of LEF-1 isoforms in a largecohort of human tumor(n=304)and tumor-free control samples(n=56).The highest expression level ofLEF-1 was found in carcinoma samples whereas brain cancer samples expressed *** of LEF-1 was different in distinct cancer *** example,the mRNA level of LEF-1 was lower in testiculartumor samples compared with tumor-free control *** epithelial cancers,significant LEF-1expression was also found in hematopoietic *** hematological malignancies,overall LEF-1 level washigher in lymphocytic leukemias compared with myeloid leukemias and normal ***,acute myeloid leukemia and acute lymphocytic leukemia showed a significantly increased fraction of theoncogenic LEF-1 compared with chronic lymphocytic leukemia and chromc myeloid *** together,these data suggest that LEF-1 is abundantly expressed in human tumors and the ratio of the oncogenic andthe dominant negative short isoform altered not only in carcinomas but also in leukemia.